CQDM started the CATALIS initiative in 2016 and created the CATALIS Québec coordination office that mobilizes all stakeholders involved in early clinical research in Quebec.
The CATALIS initiative is the materialization of the initiative in early clinical research in Quebec initiated by Montréal InVivo and its members between 2013 and 2016. It aims to position the province of Quebec on the world stage of early clinical research; and more specifically, to double private funding for early studies in Quebec by 2022.
To achieve this, the CATALIS initiative brings together important stakeholders, such as health and social services institutions in Quebec, pharmaceutical companies, contract research organizations, and other organizations dedicated to improving the clinical research environment. To engage all of its public and private partners, the initiative can count on a coordination office, CATALIS Québec, whose mandate is to coordinate the activities and development of the joint projects, as well as promote Quebec’s expertise and excellence in early stage clinical research worldwide.
Originally CATALIS Québec was hosted by CQDM. Since then, in March 2018, CATALIS Québec has become an independent non-profit organization. As a founding member, CQDM is pleased to work closely with CATALIS Québec and is proud to have contributed to the success of the initiative. CATALIS is developed as an independent organization, CQDM is proud to collaborate on the success of the initiative.
This major initiative is made possible thanks to funding from the Government of Quebec through the “Stratégie québécoise des sciences de la vie 2017-2027” as well as a contribution from the following partners: GlaxoSmithKline, Pfizer, Takeda, Abbvie, Merck, Servier, Novartis, Roche, Fonds de recherche du Québec and Innovative Medicines Canada.
For more information on the early clinical trial initiative in Quebec, visit www.catalisquebec.com.